US stock · figures in US dollars · scored on full-year results
Abbott Laboratories Abbott Laboratories Common Stock
Abbott Laboratories scores 44/100 on fundamentals: in the bottom 25% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (67/100); its weakest is Price Fairness (0/100). It carries 2 warning flags: Weak Spot, Limited Data.
- Carries a Weak Spot flag
- Carries a Limited Data flag
An expensively priced stock, but price fairness needs attention.
Nearby peers
Ranks #45 of 60 in Healthcare by score
One-Minute Summary
Why Abbott Laboratories scores 44
An expensively priced stock, but price fairness needs attention.
Business Strength
38Why 38?
No data: Quarterly Momentum
Show 3 charts
Net Profit & Equity, with ROE
Revenue & Net Profit, with Net Margin
Sales grew about 20.2% over 4 years: customers keep spending more with this company.
Profit fell about 17.9% from where it was 4 years ago: the boom has cooled off.
Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)
Sales grew about 112% over the last 8 quarters: customers keep spending more with this company.
Profit fell about 44.6% over the last 8 quarters.
Financial Safety
67Why 67?
Show 2 charts
Debt vs Equity, with D/E ratio
Borrowings grew about 117.9% over 4 years: watch this; rising debt adds pressure in bad times.
Short-term assets vs bills, with Current Ratio
Cash & Dividends
63Why 63?
Show 3 charts
Operating vs Free Cash Flow
The business generates real cash, and more of it each year: a very healthy sign.
Cash vs Total Debt
Dividends per Share, with Yield
Dividends per share have been maintained or raised: management shares the rewards with you.
Price FairnessLowest pillar
0Why 0?
Show chart
Share Price: Weekly Closes (not part of the score)
The share price is down about 12% over the past year.
Risk
50Why 50?
No data: Quarterly Consistency
Show chart
Revenue vs Inventory, with Inventory % of Revenue
Sector peers
Abbott Laboratories (ABT) scores 44/100 (Okay) on Score Your Stock's educational fundamentals model: in the bottom 25% of 503 scored S&P 500 stocks.
Its strongest pillar is Financial Safety (67/100); its weakest is Price Fairness (0/100).
Abbott Laboratories ranks #45 of 60 scored Healthcare stocks on Score Your Stock.
Yes. Abbott Laboratories (ABT) has a dividend yield of 2.4%, from dividends with an ex-date in the last 12 months. It pays out 89% of its profit as dividends. Its Cash & Dividends pillar scores 63/100.
From Malaysia, open an account with a broker that offers US shares (many local and app-based brokers do), convert ringgit to US dollars, then buy ABT. US shares trade one share at a time, not in lots of 100. Check the currency conversion fee and US dividend tax (usually 30% withheld for Malaysians) before you buy.
The overall score pools every measure across 5 weighted pillars: Business Strength, Financial Safety, Cash & Dividends, Price Fairness, and Risk. It uses the same rules as our Bursa scores. For banks, Financial Safety checks nonaccrual (impaired) loans, loan loss coverage and the CET1 capital ratio, from the FDIC call report of the group's main bank. Full methodology and the default weights: https://scoreyourstock.com/how. This is an educational tool, not investment advice.
Abbott Laboratories (ABT) is a Healthcare company (Medical Devices). On Score Your Stock's fundamentals check, it scores 44/100, rated Okay. Its biggest strength is Financial Safety (67/100); its main watch-out is Price Fairness (0/100). Shares currently cost about 39 years of its current profit to buy (P/E 39.4×). It also pays back about 2.4% of the share price as dividends each year. Full breakdown and daily-updated score: https://scoreyourstock.com/stocks/us/abt-abbott-laboratories
Full Financial History
Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.
| Financial Year | Revenue | Net Profit | Operating Cash Flow | Free Cash Flow | CapEx | Cash | Total Debt | Short-Term Debt | Equity | Current Assets | Current Liabilities | Total Assets | Total Liabilities | Inventory | Dividends | Return on Equity (ROE) | Net Profit Margin | Debt-to-Equity | Current Ratio | Interest Coverage | Dividend Payout Ratio | Div yield | P/E Ratio | P/B Ratio | PEG Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | US$ 48.2b | US$ 4.7b | US$ 9.5b | US$ 7.4b | US$ -2.1b | US$ 6.8b | US$ 34.0b | US$ 4.4b | US$ 52.1b | US$ 25.5b | US$ 18.4b | US$ 110.4b | US$ 57.7b | US$ 7.0b | - | 9% | 10% | 0.7× | 1.4× | 9.4× | 89% | - | - | - | - |
| 2025 | US$ 44.3b | US$ 6.5b | US$ 9.6b | US$ 7.4b | US$ -2.2b | US$ 8.5b | US$ 13.9b | US$ 3.0b | US$ 52.1b | US$ 26.0b | US$ 16.5b | US$ 86.7b | US$ 33.9b | US$ 6.5b | US$ 236.0m | 13% | 15% | 0.3× | 1.6× | 18.2× | 63% | 2% | 32.3× | 4.0× | - |
| 2024 | US$ 42.0b | US$ 13.4b | US$ 8.6b | US$ 6.4b | US$ -2.2b | US$ 7.6b | US$ 15.0b | US$ 1.5b | US$ 47.7b | US$ 23.7b | US$ 14.2b | US$ 81.4b | US$ 33.5b | US$ 6.2b | US$ 220.0m | 28% | 32% | 0.3× | 1.7× | 13.6× | 29% | 2% | 14.1× | 4.0× | 0.6 |
| 2023 | US$ 40.1b | US$ 5.7b | US$ 7.3b | US$ 5.1b | US$ -2.2b | US$ 6.9b | US$ 15.6b | US$ 1.1b | US$ 38.6b | US$ 22.7b | US$ 13.8b | US$ 73.2b | US$ 34.4b | US$ 6.6b | US$ 204.0m | 15% | 14% | 0.4× | 1.6× | 11.5× | 62% | 2% | 31.3× | 4.6× | 3.7 |